BioCentury | Nov 21, 2016
Strategy

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...
BC Week In Review | Jun 13, 2016
Company News

CrystalGenomics, Aptose Biosciences deal

CrystalGenomics granted Aptose an exclusive option to license rights to CG026806 outside of China and Korea. CrystalGenomics will receive an upfront payment of $1 million and is eligible for a $2 million option exercise payment...
BC Extra | Jun 9, 2016
Company News

Aptose, CrystalGenomics in deal for multi-kinase inhibitor

CrystalGenomics Inc. (KOSDAQ:083790) granted Aptose Biosciences Inc. (TSX:APS; NASDAQ:APTO) an exclusive option to license rights to CG026806 outside of China and Korea. The compound is a small molecule inhibitor of Bruton's tyrosine kinase (Btk) , FMS-like...
BioCentury | Mar 21, 2016
Product Development

Korea rising

The Korean biopharma industry is mainly known for biosimilars and me-too products. But a cohort of innovator biotechs in Korea is coming of age, bolstered by an infusion of cash from the government and by...
BC Week In Review | Feb 16, 2015
Clinical News

Acelex polmacoxib regulatory update

South Korea's Ministry of Food and Drug Safety (MFDS) approved an NDA from CrystalGenomics for Acelex polmacoxib to treat osteoarthritis. The product is a dual-acting cyclooxygenase-2 (COX-2) and carbonic anhydrase inhibitor. CrystalGenomics Inc . (KOSDAQ:083790), Seongnam,...
BC Week In Review | Feb 16, 2015
Company News

CrystalGenomics, Daewoong Pharmaceutical deal

CrystalGenomics granted Daewoong exclusive rights to commercialize Acelex polmacoxib to treat osteoarthritis in Korea. CrystalGenomics will receive an upfront payment and is eligible for milestone payments and profit sharing. The dual-acting cyclooxygenase-2 (COX-2) and carbonic...
BC Week In Review | Sep 15, 2014
Clinical News

CrystalGenomics preclinical data

In a premalignant mouse prevention study, polmacoxib was effective in reducing polyp number and size in both the small and large intestines. In a premalignant mouse treatment study, polmacoxib led to significant growth suppression of...
BC Week In Review | Jun 30, 2014
Clinical News

Polmacoxib regulatory update

CrystalGenomics disclosed it submitted an NDA last month to South Korea’s Ministry of Food and Drug Safety (MFDS) for polmacoxib to treat osteoarthritis. The company expects a decision by year end. Polmacoxib is a dual-acting...
BC Week In Review | Jun 30, 2014
Financial News

CrystalGenomics financial update

CrystalGenomics Inc. (KOSDAQ:083790), Seongnam, South Korea   Business: Infectious, Cancer, Autoimmune   Date announced:2014-06-25   Note: CrystalGenomics raised W13 billion ($13 million) from South Korea’s Ministry of Health and Welfare. The investment came from a...
BioCentury | Jun 30, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Basilea Pharmaceutica AG (SIX:BSLN) fell CHF9.10 to CHF104.90 last week after it said FDA confirmed additional Phase III data would be required to support U.S. approval of ceftobiprole to treat pneumonia. The company...
Items per page:
1 - 10 of 37
BioCentury | Nov 21, 2016
Strategy

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...
BC Week In Review | Jun 13, 2016
Company News

CrystalGenomics, Aptose Biosciences deal

CrystalGenomics granted Aptose an exclusive option to license rights to CG026806 outside of China and Korea. CrystalGenomics will receive an upfront payment of $1 million and is eligible for a $2 million option exercise payment...
BC Extra | Jun 9, 2016
Company News

Aptose, CrystalGenomics in deal for multi-kinase inhibitor

CrystalGenomics Inc. (KOSDAQ:083790) granted Aptose Biosciences Inc. (TSX:APS; NASDAQ:APTO) an exclusive option to license rights to CG026806 outside of China and Korea. The compound is a small molecule inhibitor of Bruton's tyrosine kinase (Btk) , FMS-like...
BioCentury | Mar 21, 2016
Product Development

Korea rising

The Korean biopharma industry is mainly known for biosimilars and me-too products. But a cohort of innovator biotechs in Korea is coming of age, bolstered by an infusion of cash from the government and by...
BC Week In Review | Feb 16, 2015
Clinical News

Acelex polmacoxib regulatory update

South Korea's Ministry of Food and Drug Safety (MFDS) approved an NDA from CrystalGenomics for Acelex polmacoxib to treat osteoarthritis. The product is a dual-acting cyclooxygenase-2 (COX-2) and carbonic anhydrase inhibitor. CrystalGenomics Inc . (KOSDAQ:083790), Seongnam,...
BC Week In Review | Feb 16, 2015
Company News

CrystalGenomics, Daewoong Pharmaceutical deal

CrystalGenomics granted Daewoong exclusive rights to commercialize Acelex polmacoxib to treat osteoarthritis in Korea. CrystalGenomics will receive an upfront payment and is eligible for milestone payments and profit sharing. The dual-acting cyclooxygenase-2 (COX-2) and carbonic...
BC Week In Review | Sep 15, 2014
Clinical News

CrystalGenomics preclinical data

In a premalignant mouse prevention study, polmacoxib was effective in reducing polyp number and size in both the small and large intestines. In a premalignant mouse treatment study, polmacoxib led to significant growth suppression of...
BC Week In Review | Jun 30, 2014
Clinical News

Polmacoxib regulatory update

CrystalGenomics disclosed it submitted an NDA last month to South Korea’s Ministry of Food and Drug Safety (MFDS) for polmacoxib to treat osteoarthritis. The company expects a decision by year end. Polmacoxib is a dual-acting...
BC Week In Review | Jun 30, 2014
Financial News

CrystalGenomics financial update

CrystalGenomics Inc. (KOSDAQ:083790), Seongnam, South Korea   Business: Infectious, Cancer, Autoimmune   Date announced:2014-06-25   Note: CrystalGenomics raised W13 billion ($13 million) from South Korea’s Ministry of Health and Welfare. The investment came from a...
BioCentury | Jun 30, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Basilea Pharmaceutica AG (SIX:BSLN) fell CHF9.10 to CHF104.90 last week after it said FDA confirmed additional Phase III data would be required to support U.S. approval of ceftobiprole to treat pneumonia. The company...
Items per page:
1 - 10 of 37